Did you know? You can suggest edits to improve this peptide information.
Overview
What is SS-31 (Elamipretide)?
SS-31, also known as Elamipretide or Bendavia, is a small aromatic-cationic tetrapeptide that selectively targets mitochondria. Unlike traditional antioxidants, SS-31 specifically binds to cardiolipin in the inner mitochondrial membrane, protecting it from oxidative damage and improving cellular energy production. This unique mechanism makes it particularly promising for age-related conditions, heart disease, and mitochondrial disorders.
Key Benefits
Directly protects mitochondria, improves cellular energy, reduces oxidative damage, enhances exercise capacity
Mechanism of Action
Selectively binds to cardiolipin in inner mitochondrial membrane, preventing lipid peroxidation and optimizing electron transport chain function
Pharmacokinetics
Research Indications
Enhanced ATP Production
Improves mitochondrial efficiency and cellular energy generation
Oxidative Stress Reduction
Protects against reactive oxygen species at the source
Mitochondrial Disease Support
Shows promise for various mitochondrial disorders
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Morning dosing recommended to align with natural circadian rhythms of mitochondrial function. Pre-workout timing for athletic applications.
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
Clean vial top with alcohol pad
Add appropriate amount of bacteriostatic water (typically 1-2mL per 10mg)
Gently swirl to dissolve - SS-31 dissolves readily
Solution should be clear and colorless
For IV use, may require sterile filtration
Label with concentration and date
Store in refrigerator immediately
Quality Indicators
Pharmaceutical grade
SS-31 requires high purity due to clinical use - look for >98% purity
Clear solution
Should dissolve completely into clear, colorless solution
COA available
Certificate of analysis essential due to clinical applications
Light sensitive
Protect from light exposure - use amber vials if available
pH considerations
Solution pH should be near physiological (6.5-7.5)
Discoloration
Any yellow or brown color indicates degradation
What to Expect
- Day 1-3: Subtle energy improvements, reduced fatigue
- Week 1-2: Better exercise endurance, faster recovery
- Week 2-4: Improved stamina, clearer thinking, better sleep quality
- Week 4-8: Significant improvements in exercise capacity
- Week 8-12: Sustained energy improvements, potential biomarker changes
Side Effects & Safety
- Excellent safety profile in clinical trials
- No significant side effects reported at therapeutic doses
- May cause mild injection site reactions
- Monitor for allergic reactions (very rare)
- Safe for long-term use based on current data
- No known drug interactions
References
Barth Syndrome Clinical Trial - FDA Approval (2025)
Led to FDA accelerated approval of FORZINITY (elamipretide) in September 2025 - the first mitochondrial-targeting therapy approved. Indicated for improving muscle strength in Barth syndrome patients ≥30kg.
Phase 2 Trial for Primary Mitochondrial Myopathy (2018)
Showed significant improvements in 6-minute walk test and fatigue scores in patients with mitochondrial myopathies, with excellent safety profile and no serious adverse events.
Cardioprotection in Heart Failure Model (2019)
Reduced cardiac injury markers and improved mitochondrial function in patients undergoing cardiac surgery, suggesting powerful cardioprotective effects.
Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia